Dimethyl Sulfoxide
Medchemexpress LLC Ru.521 10Mm Dmso Solid 1Nl | HY-114180-10MM DMSO SOLID
Ru.521 10Mm Dmso Solid 1Nl
Apexbio Technology LLC Fingolimod (FTY720) 162359-56-0 10mM (in 1mL DMSO)
Fingolimod (FTY720 CAS 162359-56-0) is an orally administered sphingosine-1-phosphate (S1P) receptor agonist structurally analogous to natural sphingosine Originally derived from fungal metabolites and initially investigated in organ transplantation fingolimod interacts potently with receptors S1P1 S1P3 S1P4 and S1P5 (EC50 values approximately 0 3 3 1 nM) Its agonism promotes receptor internalization suppressing lymphocyte migration from lymph nodes into the circulation and central nervous system (CNS) Thus fingolimod is studied primarily for autoimmune disorders especially multiple sclerosis due to its effects on lymphocyte trafficking and CNS infiltration
Selleck Chemical LLC OSS_128167, 10mM (1mL in DMSO)
OSS_128167 (SIRT6-IN-1) is a specific SIRT6 inhibitor with IC50 values of 89, 1578 and 751 μM for SIRT6, SIRT1 and SIRT2, respectively. OSS_128167 has anti-viral effect in HBV transcription and replication.
Medchemexpress LLC Dm4 Solution 10Mm1Ml In Dmso | HY-12454-10MM1ML/DMSO SOL
Dm4 Solution 10Mm1Ml In Dmso
eMolecules 2168-93-6 | n-Butyl sulfoxide | Oakwood Chemicals | MFCD00002093 | 162.290 | C8H18OS | 96.000 | CCCCS(=O)CCCC | 25g | 480102057
n-Butyl sulfoxide | Oakwood Chemicals | 2168-93-6 | MFCD00002093 | 162.290 | C8H18OS | 96.000 | CCCCS(=O)CCCC | 25g | 480102057
Medchemexpress LLC Dnl343 Solution 10Mm 1Ml Dmso | HY149555-10MM 1ML DMSO
Dnl343 Solution 10Mm 1Ml Dmso
Medchemexpress LLC Bay-9835 10Mm Dmso Reconst 1Ml | HY-162284-10MM-DMSO-RECON
Bay-9835 10Mm Dmso Reconst 1Ml
Apexbio Technology LLC PCI-34051(Synonyms: PCI 34051, PCI34051, HDAC8 inhibitor PCI-34051, PCI-34051 HDAC inhibitor), 10mM (in 1mL DMSO), CAS: 950762-95-5.
PCI-34051 (CAS 950762-95-5) is a selective inhibitor of histone deacetylase 8 (HDAC8) with over 200-fold specificity compared to other HDAC isoforms including HDAC1 HDAC2 HDAC3 HDAC6 and HDAC10 Through selective HDAC8 inhibition PCI-34051 preferentially triggers caspase-dependent apoptosis in T-cell lymphoma and leukemia-derived cell lines while sparing normal hematopoietic (e g PBMCs) and fibroblast cells Cell death induction by PCI-34051 occurs without detectable histone or tubulin hyperacetylation This compound serves as a valuable research tool for dissecting HDAC8-related pathways and evaluating therapeutic potential for hematologic malignancies
Apexbio Technology LLC Clopidogrel 120202-66-6 10mM (in 1mL DMSO)
Clopidogrel (CAS 120202-66-6) is a selective antagonist targeting the platelet P2Y receptor thereby preventing ADP-mediated platelet activation and aggregation Through this mechanism clopidogrel exhibits pronounced antithrombotic properties reducing thrombus formation It is the pharmacologically active enantiomer derived from racemic ( )-clopidogrel hydrochloride Clopidogrel is widely employed in biomedical research examining platelet function thrombosis pathways and therapeutic interventions targeting cardiovascular disease
Apexbio Technology LLC AZD6244 (Selumetinib) 606143-52-6 10mM (in 1mL DMSO)
AZD6244 (Selumetinib CAS 606143-52-6) is a small-molecule inhibitor selectively targeting MEK1/2 components of the MAP kinase signaling cascade It inhibits MEK1 via a non-ATP-competitive mechanism with an IC50 of 14 1 nM leading to decreased phosphorylation of downstream targets ERK1/2 (IC50 10 3 nM cellular assays) AZD6244 exhibits minimal off-target activity against related kinases including MKK6 EGFR ErbB2 and B-Raf In tumor cell lines harboring activated Ras or B-Raf mutations AZD6244 reduces cell proliferation and inhibits growth in xenograft models Thus AZD6244 is useful for investigating MAP kinase pathway-driven malignancies
Apexbio Technology LLC SP 600125 129-56-6 10mM (in 1mL DMSO)
SP 600125 (CAS 129-56-6) is a selective reversible ATP-competitive inhibitor of c-Jun N-terminal kinase (JNK) with reported IC50 values of 40 nM for JNK1 and JNK2 and 90 nM for JNK3 Initially identified via GST-c-Jun substrate and recombinant human JNK2 screening assays SP 600125 demonstrates marked specificity being approximately 300-fold more selective toward JNK isoforms compared to ERK1 and p38-2 kinases In cellular assays SP 600125 effectively suppresses JNK-mediated phosphorylation of c-Jun and attenuates expression of IL-2 IFN- and TNF- It is widely utilized in inflammation and signal transduction research
Apexbio Technology LLC MDL 28170 88191-84-8 10mM (in 1mL DMSO)
MDL 28170 (CAS 88191-84-8) is a selective inhibitor of calpain and cathepsin B with Ki values of approximately 10 nM and 25 nM respectively It acts by directly blocking the catalytic site of these cysteine proteases without inhibiting serine proteases MDL 28170 readily penetrates the blood-brain barrier inhibiting protease activity in brain tissue and mitigating ischemia-induced neurological damage in animal models The compound reduces muscle fiber sensitivity to calcium influx post-ischemia and limits myocardial injury caused by calcium overload It also exhibits antiparasitic activity in vitro significantly lowering Trypanosoma cruzi survival in infected macrophages MDL 28170 is used in biomedical research to study protease-related pathology ischemic injury and parasite-host interactions
Apexbio Technology LLC LMK 235 1418033-25-6 10mM (in 1mL DMSO)
LMK 235 (CAS 1418033-25-6) is a histone deacetylase (HDAC) inhibitor exhibiting preferential selectivity against HDAC4 and HDAC5 isoforms HDAC enzymes (EC 3 5 1 98) catalyze the removal of acetyl groups from lysine residues on histone proteins influencing DNA-histone interactions and gene expression In vitro LMK 235 demonstrates potent inhibition at nanomolar concentrations against HDAC4/5 and notable cytotoxic effects toward multiple cancer cell lines including A2780 Cal27 Kyse510 and MDA-MB231 In animal studies LMK 235 enhances the antitumor efficacy of cytarabine suggesting applications in overcoming chemoresistance in leukemia models Currently LMK 235 remains under preclinical investigation
Apexbio Technology LLC LY2835219 1231930-82-7 10mM (in 1mL DMSO)
LY2835219 (CAS 1231930-82-7) is a selective orally bioavailable inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) It targets CDK4 and CDK6 with reported IC50 values of 2 nM and 10 nM respectively thereby reducing phosphorylation of the retinoblastoma protein (Rb) This mechanism leads to cell-cycle arrest during the G1 phase and subsequent inhibition of tumor cell proliferation LY2835219 demonstrates the capacity to cross the blood-brain barrier indicating its potential utility in research involving primary or metastatic intracranial tumors